Lycopodium Limited

As of June 30, 2026, Lycopodium Limited carries a market capitalization of 495.59M, placing it among publicly traded companies globally. Its enterprise value stands at 430.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lycopodium Limited's next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Lycopodium Limited has 39.74M shares outstanding.

As of June 30, 2026, Lycopodium Limited trades at a trailing price-to-earnings ratio of 17.83. The price-to-sales ratio is 1.91, and the price-to-book ratio stands at 4.21.

As of June 30, 2026, Lycopodium Limited trades at an EV/EBITDA multiple of 11.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.90 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 430.91M versus a market cap of 495.59M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Lycopodium Limited maintains a current ratio of 2.17, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.32, indicating elevated leverage, while an interest coverage ratio of 243.24 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Lycopodium Limited posted a return on equity (ROE) of 24.96, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 19.53 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 15.03, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 22.82, useful for judging operating efficiency across full business cycles.

Over the twelve months ended June 30, 2026, Lycopodium Limited recorded 8.24M in income tax expense. That works out to an effective tax rate of 22.68, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 36.31M, leaving 27.80M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on August 20, 2026, Lycopodium Limited's stock has gained approximately 96.13% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Lycopodium Limited generated 258.84M in revenue and converted that into 27.80M in net income, yielding earnings per share of 0.71. EBITDA reached 36.36M, while operating income came in at 31.00M.

As of June 30, 2026, Lycopodium Limited holds 73.83M in cash and equivalents against 8.64M in total debt, resulting in a net debt position of -72.63M. Total book value stands at 117.61M, with working capital of 91.96M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Lycopodium Limited posted a gross margin of 90.00, reflecting its pricing power and cost economics. The operating margin of 11.98 and net profit margin of 10.74 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Lycopodium Limited paid dividends of 0.33 per share. The dividend payout ratio of 45.61 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Lycopodium Limited shareholders.

As of June 30, 2026, Lycopodium Limited has an Altman Z-Score of 6.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.